

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Gaush Meditech Ltd

高视医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2407)

VOLUNTARY ANNOUNCEMENT

RELEASE OF SHARE CHARGE BY CONTROLLING SHAREHOLDER

This announcement is made by Gaush Meditech Ltd (the “**Company**”) on a voluntary basis. Reference is made to (i) the prospectus of the Company dated November 30, 2022 in relation to the listing of the shares of the Company (the “**Shares**”) on the Main Board of The Stock Exchange of Hong Kong Limited; (ii) the announcement of the Company dated January 4, 2023 in relation to, among others, the partial exercise of the over-allotment option (the “**Over-allotment Option**”) and the end of the stabilization period; and (iii) the announcement of the Company dated January 6, 2023 (the “**Announcement**”) in relation to, among others, the charge of Shares by GAUSH HOLDING Ltd (“**GT HoldCo**”), a controlling shareholder of the Company. Unless otherwise defined, capitalised terms used herein have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, GT HoldCo informed the Company that it had entered into a facility agreement (the “**Facility Agreement**”) with Credit Suisse, pursuant to which Credit Suisse granted a loan facility of HK\$185,000,000 (the “**Facility**”) to GT HoldCo. As security for the Facility, GT HoldCo agreed to charge 38,972,718 Shares (the “**Charged Shares**”) in favour of Credit Suisse. In addition, as the Over-allotment Option was only partially exercised, GT HoldCo has requested that 500,422 Shares of the Charged Shares be released in accordance with the Facility Agreement, and immediately following such release, the number of the remaining Charged Shares is 38,472,296, representing approximately 26.00% of the total issued Shares as of the date of this announcement.

GT Holdco recently informed the Company that (i) the Facility of HK\$185,000,000 granted by Credit Suisse to GT Holdco had been fully repaid by GT Holdco with its self-owned idle funds; and (ii) GT Holdco had entered into a deed of release with Credit Suisse on April 6, 2023, pursuant to which the Charged Shares had been released in full with effect from April 6, 2023.

As of the date of this announcement, GT Holdco is wholly owned by Mr. Gao Tieta, the chairman of the Board, an executive Director and a controlling shareholder of the Company. As of the date of this announcement, GT Holdco held 63,263,528 Shares, representing approximately 42.75% of the total issued Shares, and none of the Shares held by GT Holdco were subject to any share charge.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares.

By order of the Board
Gaush Meditech Ltd
Mr. Gao Tieta
Chairman and Executive Director

Hong Kong, April 13, 2023

As of the date of this announcement, the Board comprises Mr. Gao Tieta as Chairman and executive Director, Mr. Liu Xinwei, Mr. Zhao Xinli and Mr. Zhang Jianjun as executive Directors, Dr. David Guowei Wang and Mr. Shi Long as non-executive Directors, and Mr. Feng Xin, Mr. Wang Li-Shin and Mr. Chan Fan Shing as independent non-executive Directors.